ZVRA vs. EDD

Last updated Aug 1, 2026

ZVRA (Zevra Therapeutics Inc.) is a stock, while EDD (Morgan Stanley Emerging Markets Domestic Fund) is Emerging Markets Bonds fund managed by Morgan Stanley. Over the past 10 years, ZVRA returned -17.62%/yr vs 5.50%/yr for EDD. Their 0.13 correlation means their historical movements had little consistent relationship.

Performance

ZVRA vs. EDD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Zevra Therapeutics Inc. (ZVRA) and Morgan Stanley Emerging Markets Domestic Fund (EDD). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ZVRA achieves a 6.14% return, which is significantly lower than EDD's 14.80% return. Over the past 10 years, ZVRA has underperformed EDD with an annualized return of -17.62%, while EDD has yielded a comparatively higher 5.50% annualized return.

ZVRA

• 1D: -1.35%
• 1M: -31.14%
• 6M: 5.67%
• YTD: 6.14%
• 1Y: -14.40%
• 3Y*: 24.74%
• 5Y*: -1.18%
• 10Y*: -17.62%
• ALL TIME*: -23.23%

EDD

• 1D: -0.17%
• 1M: 0.69%
• 6M: 6.55%
• YTD: 14.80%
• 1Y: 27.62%
• 3Y*: 18.63%
• 5Y*: 8.18%
• 10Y*: 5.50%
• ALL TIME*: 2.96%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
EDD Morgan Stanley Emerging Markets Domestic Fund	$2.10M	$3.03M	$2.42M
ZVRA Zevra Therapeutics Inc.	$18.33M	$18.68M	$21.76M

ZVRA vs. EDD - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ZVRA Zevra Therapeutics Inc.	6.14%	7.43%	27.33%	42.70%	-47.30%	-22.23%	84.70%	-78.71%	-56.05%	37.29%
EDD Morgan Stanley Emerging Markets Domestic Fund	14.80%	32.46%	8.64%	14.09%	-14.15%	-7.03%	-2.84%	25.45%	-14.09%	16.34%

Correlation

The correlation between ZVRA and EDD is 0.08, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.08
Correlation (3Y) Balances recent behavior with more history.	0.09
Correlation (5Y) Shows whether the relationship held over a longer period.	0.15
Correlation (10Y) Provides a long-term view across more market conditions.	0.12
Correlation (All Time) Calculated using the full available price history since Apr 16, 2015	0.13

Return for Risk

ZVRA vs. EDD — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

ZVRA

ZVRA Risk / Return Rank: 34
ZVRA Sharpe Ratio Rank: 34
ZVRA Sortino Ratio Rank: 36
ZVRA Omega Ratio Rank: 37
ZVRA Calmar Ratio Rank: 32
ZVRA Martin Ratio Rank: 31

EDD

EDD Risk / Return Rank: 57
EDD Sharpe Ratio Rank: 73
EDD Sortino Ratio Rank: 70
EDD Omega Ratio Rank: 69
EDD Calmar Ratio Rank: 38
EDD Martin Ratio Rank: 35

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

ZVRA vs. EDD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Zevra Therapeutics Inc. (ZVRA) and Morgan Stanley Emerging Markets Domestic Fund (EDD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	ZVRA	EDD	Difference
Sharpe ratio: Return per unit of total volatility	-0.22	1.66	-1.88
Sortino ratio: Return per unit of downside risk	0.13	2.32	-2.19
Omega ratio: Gain probability vs. loss probability	1.02	1.29	-0.28
Calmar ratio: Return relative to maximum drawdown	-0.36	1.57	-1.93
Martin ratio: Return relative to average drawdown	-0.65	5.03	-5.68

ZVRA vs. EDD - Sharpe Ratio Comparison

The current ZVRA Sharpe Ratio is -0.22, which is lower than the EDD Sharpe Ratio of 1.66. The chart below compares the historical Sharpe Ratios of ZVRA and EDD, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

ZVRA vs. EDD - Drawdown Comparison

The maximum ZVRA drawdown since its inception was -99.27%, which is greater than EDD's maximum drawdown of -59.38%. Use the drawdown chart below to compare losses from any high point for ZVRA and EDD.

Drawdown Indicators

	ZVRA	EDD	Difference
Max Drawdown Largest peak-to-trough decline	-99.27%	-59.38%	-39.89%
Max Drawdown (1Y) Largest decline over 1 year	-40.40%	-17.67%	-22.73%
Max Drawdown (3Y) Largest decline over 3 years	-43.47%	-17.67%	-25.80%
Max Drawdown (5Y) Largest decline over 5 years	-60.97%	-32.04%	-28.93%
Max Drawdown (10Y) Largest decline over 10 years	-97.85%	-42.70%	-55.15%
Current Drawdown Current decline from peak	-97.48%	-2.84%	-94.64%
Average Drawdown Average peak-to-trough decline	-86.53%	-24.06%	-62.47%
Ulcer Index Depth and duration of drawdowns from previous peaks	22.22%	5.50%	+16.72%

Volatility

ZVRA vs. EDD - Volatility Comparison

Zevra Therapeutics Inc. (ZVRA) has a higher volatility of 29.44% compared to Morgan Stanley Emerging Markets Domestic Fund (EDD) at 4.62%. This indicates that ZVRA's price experiences larger fluctuations and is considered to be riskier than EDD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ZVRA	EDD	Difference
Volatility (1M) Calculated over the trailing 1-month period	29.44%	4.62%	+24.82%
Volatility (6M) Calculated over the trailing 6-month period	49.17%	13.86%	+35.31%
Volatility (1Y) Calculated over the trailing 1-year period	65.35%	16.72%	+48.63%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	61.11%	15.57%	+45.54%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	81.05%	17.66%	+63.39%

Dividends

ZVRA vs. EDD - Dividend Comparison

ZVRA has not paid dividends to shareholders, while EDD's dividend yield for the trailing twelve months is around 10.82%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
EDD Morgan Stanley Emerging Markets Domestic Fund	10.82%	9.76%	11.45%	7.30%	6.82%	6.93%	6.92%	8.15%	9.90%	8.18%	10.32%	12.65%
ZVRA Zevra Therapeutics Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Can I hold both ZVRA and EDD in my portfolio?

ZVRA and EDD have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ZVRA or EDD?

ZVRA has higher volatility (29.44%) compared to EDD (4.62%). In terms of maximum drawdown, ZVRA dropped -99.27% vs EDD's -59.38%.

Which has better risk-adjusted returns?

EDD currently has the higher Sharpe Ratio (1.66 vs -0.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.